Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 127 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical VEHICLE cream Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

NCT00525499
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ASC-J9 cream, placebo
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 18, 2026, 11:59 AM EDT
Withdrawn Phase 3 Interventional

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

NCT05219864
View directory record Official record
Conditions
Hand Eczema
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Encino, California • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

NCT04896385
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation

NCT01066585
View directory record Official record
Conditions
Head Lice
Interventions
Ivermectin Cream, vehicle control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
6 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Yuma, Arizona • Dinuba, California • Plantation, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris

NCT02661958
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-1, S6G5T-5, S6G5T-6, S6G5T-7, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

NCT05635838
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

NCT03683719
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Tucson, Arizona • Hialeah, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745638
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser

NCT02427724
View directory record Official record
Conditions
Lentigo
Interventions
lidocaine 2.5%/prilocaine 2.5% topical anesthetic, lidocaine 7%/tetracaine 7% topical anesthetic, placebo vehicle, Q-switched 532nm Laser
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris

NCT03173547
View directory record Official record
Conditions
Ichthyosis Vulgaris
Interventions
146-9251 cream, Vehicle cream
Drug
Lead sponsor
Crown Laboratories, Inc.
Industry
Eligibility
12 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • Plainfield, Indiana • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

NCT05593445
View directory record Official record
Conditions
Lichen Sclerosus
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 18, 2026, 11:59 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

NCT03539601
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 18, 2026, 11:59 AM EDT
Recruiting Phase 2 Interventional

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029
View directory record Official record
Conditions
Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia, Vulvary Pain Disorders, Neuroproliferative Vestibulodynia, Mast Cell-mediated Neuroinflammation, Instertional Dyspareunia
Interventions
Ketotifen Fumarate 0.25% Cream, Placebo (Vehicle Cream)
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 1 Interventional

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

NCT05675501
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Encapsulated Benzoyl Peroxide Cream
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers

NCT05279495
View directory record Official record
Conditions
Photoaging
Interventions
In a double-blinded fashion, 250 mg CANNAXR cream, Topical VEHICLE cream
Device
Lead sponsor
MINO Labs, LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01241331
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, Vehicle cream
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • Oceanside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

NCT03956355
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof, Vehicle Cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 18, 2026, 11:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

NCT03954236
View directory record Official record
Conditions
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Interventions
topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 18, 2026, 11:59 AM EDT
Completed Phase 3 Interventional

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563394
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 18, 2026, 11:59 AM EDT